Artelo Biosciences, Inc. (ARTL) stock
ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.18 (-10.71%)
Close on Nov 18, 2026Market cap $1.01MP/E –Yield –
Artelo Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Artelo Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$12.63M. For fiscal 2025 it was -$8.52M. The highest annual figure on record is -$13.50K in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.52M | – |
| FY2024 | Dec 31, 2024 | -$8.35M | – |
| FY2023 | Dec 31, 2023 | -$8.21M | – |
| FY2021 | Aug 31, 2021 | -$6.14M | – |
| FY2020 | Aug 31, 2020 | -$4.35M | – |
| FY2019 | Aug 31, 2019 | -$2.79M | – |
| FY2018 | Aug 31, 2018 | -$1.61M | – |
| FY2017 | Aug 31, 2017 | -$216.82K | – |
| FY2016 | Aug 31, 2016 | -$18.49K | – |
| FY2015 | Aug 31, 2015 | -$13.50K | – |
| FY2014 | Aug 31, 2014 | -$15.27K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$5.03M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$1.19M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$2.91M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$3.50M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$514.00K | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$1.60M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$2.57M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$778.00K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$2.06M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$2.94M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$2.60M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$1.80M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$1.62M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$2.19M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$1.54M | – |
| Q3 FY2021CQ2 2021 | May 31, 2021 | -$1.78M | – |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | -$1.50M | – |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | -$1.32M | – |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | -$872.33K | – |
| Q3 FY2020CQ2 2020 | May 31, 2020 | -$1.02M | – |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | -$1.40M | – |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | -$1.05M | – |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | -$1.06M | – |
| Q3 FY2019CQ2 2019 | May 31, 2019 | -$589.45K | – |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | -$740.97K | – |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | -$401.15K | – |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | -$513.87K | – |
| Q3 FY2018CQ2 2018 | May 31, 2018 | -$458.77K | – |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | -$467.49K | – |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | -$169.89K | – |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | -$157.96K | – |
| Q3 FY2017CQ2 2017 | May 31, 2017 | -$36.67K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | -$9.79K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | -$12.41K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $0 | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$3.85K | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | -$381 | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | -$14.26K | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | -$2.85K | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | -$4.00K | – |
See a number that looks wrong?